Drug Trial Radar · NCT06001684
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Sep 1, 2023
Primary completion
Dec 26, 2024
Study completion Dec 26, 2024
Sponsor
- Lead sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
Conditions
- Solid Tumors
Interventions
IBR854 Cell InjectionBiological
The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLTs)Time frame: From day1 to day 21
- The incidence and severity of adverse events (AEs)Time frame: From day 1 to day 90 after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.